Back to top

Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT)

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on EyePoint Pharmaceuticals today and set a price target of $36.00. Suvannavejh...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

EyePoint, Inc. (EYPT)